CIC-EC 1432 - Dijon

Who are we?

The CIC-EC 1432 has for mission to provide a methodological and logistical help to all stages of clinical epidemiology studies (cohort follow-up, studies of care practice, diagnostic studies,…) and randomized trials phase III or IV multicenter, including notably a medico-economic side. The activity of the CIC-EC takes place in the strategic axes of Dijon research site (Cancer and precancerous pathologies; Sensory, motor and cognitive incapacities; immune response, inflammation, infection; rare diseases). The CIC-EC has, furthermore, initiated a transverse axis “Patient/Health/Society” putting the patient (and/or his entourage), his social and societal environment at the core of the research concerns. It aims more specifically to assess the links between the socio-economic conditions and the patient care or outcome, the quality of life of patients (and/or their families), the role of the patient (and/or families) in the logistic of decision making.
Currently, the CIC-EC participates in more than 50 research projects, in most of which, it is strongly involved from the conception to the valorization. These studies are made in partnership with clinical teams and researchers of labeled teams of the research site (Research center Inserm U1231, notably team “Epidémiologie et recherche Clinique en cancérologie digestive”, Labex LipSTIC, U1093 “cognition, action, plasticité sensorimotrice”, FHU TRANSLASD and INCREASE, Centre for Taste and Feeding Behavior…), in coordination with the pluri-thematic unit of the CIC, and the other support structures to clinical research of the site. The CIC is heavily involved in the networks Quali-CIC, RECaP, REDSIAM and the national platform “quality of life and cancer” and develops partnerships with study groups and international consortiums (GTE, FFCD, E³,…). Since 2016, it also i involved in the pilot studies of Plan France Médecine Génomique 2025, in close collaboration with other RECaP teams.

Main publications

• Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F, Bruyère R, [..], Binquet C, Quenot JP. Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis. N Engl J Med, 2018; 379: 1431-1442
• Vinault S, Mariet AS, Le Bras M, Mirallié E, Cardot-Bauters C, Pattou F, […], Binquet C, Goudet P. Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study. Ann Surg 2018 ;
• Meunier-Beillard N, Ponthier N, Lepage C, Gagnaire A, Ghiringuelli F, Bengrine L, Boudrant A, Rambach L, Quipourt V, Devilliers H, Lejeune C. Identification of resources and skills developed by partners of patients with advanced colon cancer: a qualitative study. Support Care Cancer. 2018;26:4121-4131.
• Schneider M, Mosca M, Pego-Reigosa JM, Gunnarsson I, Maurel F, Garofano A, Perna A, Porcasi R, Devilliers H. Cross-cultural validation of Lupus Impact Tracker in five European clinical practice settings. Rheumatology 2017;56:818-828.
• Piroth L, Launay O, Michel ML, Bourredjem A, Miailhes P, Ajana F, Chirouze C, Zucman D, Wendling MJ, Nazzal D, Carrat F, Rey D, Binquet C; ANRS HB EP03 CISOVAC Study Group. Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. J Infect Dis 2016; 213:1735-42.
• Cousin F, Ortega-Deballon P, Bourredjem A, Doussot A, Giaccaglia V, Fournel I.  Diagnostic accuracy of Procalcitonin and C-reactive protein for the early diagnosis of intra-abdominal infection after elective colorectal surgery: a meta-analysis. Annals of Surgery 2016;264:252-256

Contact us

CIC-EC Inserm CIC1432
UFR des Sciences de Santé
7, bd Jeanne d’Arc
21000 Dijon
03.80.39.33.92
christine.binquet@u-bourgogne.fr